Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCA: Colchicine + BMS vs DES after PCI
NCT04382443Phase 4Completed
- Sponsor
- Centro de Estudios en Cardiología Intervencionista
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of colchicine in coronary artery disease (CAD), in-stent restenosis (ISR), atherosclerosis and 1 more, sponsored by Centro de Estudios en Cardiología Intervencionista. Primary endpoint: Major Adverse Cardiac Events at 365 days. Started Mar 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)in-stent restenosis (ISR)atherosclerosisacute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04382443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382443.